Insmed (INSM) Misses Q2 EPS by 65c, beats revenue, provides guidance

Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.78), $0.65 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $77.2 million versus the consensus estimate of $71.01 million.

Guidance:
Insmed is raising its sales guidance for full-year 2023 global revenues for ARIKAYCE to a range of $295 million to $305 million from a range of $285 million to $300 million previously.

For earnings history and earnings-related data on Insmed (INSM) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Top restaurant stocks to watch, according to Raymond James
• AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says